Novartis’ Gilenya Improves Cognition, Reduces Relapses and MS Lesions, Phase 4 Trial Shows

Novartis’ Gilenya Improves Cognition, Reduces Relapses and MS Lesions, Phase 4 Trial Shows

Thirty patients discontinued the study. A lot more were in the interferon beta-1b group than in  the Gilenya  group — 41 percent versus 8 percent.

Both therapies improved patients’ cognition, the trial showed. But patients in the interferon beta-1b group had more relapses and brain lesions than the Gilenya-treated patients.

Overall, the results supported the notion that both therapies can improve MS patients’ cognition. But “despite a disadvantage in terms of baseline characteristics [severity of the disease] and drop-out patterns, fingolimod treatment demonstrated significantly better effects than interferon beta-1 on MRI parameters and relapse rate,” the team concluded.

2 comments

Leave a Comment

Your email address will not be published. Required fields are marked *